Risk factors for the progression of cystic fibrosis lung disease throughout childhood

Annals of the American Thoracic Society

Volumn 11, Issue 1, 2014, Pages 63-72

  Sanders, Don B ^a   Li, Zhanhai ^a   Laxova, Anita ^a   Rock, Michael J ^a   Levy, Hara ^b   Collins, Jannette ^c   Ferec, Claude ^d   Farrell, Philip M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

Chest X ray; Newborn screening; Nutrition; Pulmonary function test; Sex

Indexed keywords

AZITHROMYCIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; SODIUM CHLORIDE; TOBRAMYCIN;

ADOLESCENT; ARTICLE; BODY MASS; BURKHOLDERIA CEPACIA COMPLEX; CHILD GROWTH; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; CONTROLLED STUDY; CRACKLE; CYSTIC FIBROSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; GROWTH DISORDER; HUMAN; LUNG AUSCULTATION; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MECONIUM ILEUS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PSEUDOMONAS INFECTION; RISK FACTOR; SCORING SYSTEM; SPUTUM CULTURE; THORAX RADIOGRAPHY; WISCONSIN CHEST X RAY SCORE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; FEMALE; GENOTYPE; HOSPITALIZATION; HUMANS; ILEUS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; LUNG; MALE; MECONIUM; NEONATAL SCREENING; NUTRITION DISORDERS; OLIGOPEPTIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; YOUNG ADULT;

EID: 84893436317     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201309-303OC     Document Type: Article

References (70)

1. Cystic Fibrosis Foundation. 2011 patient registry annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2012 [accessed 2013 Aug 26]. Available from: http://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient- Registry.pdf
2. Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S, Stokes D, Wohl M, Wagener J, Regelmann W, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-139, 139.e1.
3. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-66.
4. Zemel BS, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 2000; 137:374-380.
5. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400.
6. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163:1331-1337. (Pubitemid 32506595)
7. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, et al.; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453. (Pubitemid 41400918)
8. Levy H, Murphy A, Zou F, Gerard C, Klanderman B, Schuemann B, Lazarus R, García KC, Celedón JC, Drumm M, et al. IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol 2009;44:580-593.
9. Li Z, Lai HJ, Kosorok MR, Laxova A, Rock MJ, Splaingard ML, Farrell PM. Longitudinal pulmonary status of cystic fibrosis children with meconium ileus. Pediatr Pulmonol 2004;38:277-284. (Pubitemid 39245108)
10. Kraemer R, Deloséa N, Ballinari P, Gallati S, Crameri R. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006;174: 1211-1220. (Pubitemid 44924822)
11. Braun AT, Farrell PM, Ferec C, Audrezet MP, Laxova A, Li Z, Kosorok MR, Rosenberg MA, Gershan WM. Cystic fibrosis mutations and genotype-pulmonary phenotype analysis. J Cyst Fibros 2006;5:33-41. (Pubitemid 43137159)
12. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-814. (Pubitemid 28027602)
13. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010;182:614-626.
14. Truby H, Paxton AS. Body image and dieting behavior in cystic fibrosis. Pediatrics 2001;107:E92.
15. Willis E, Miller R, Wyn J. Gendered embodiment and survival for young people with cystic fibrosis. Soc Sci Med 2001;53:1163-1174. (Pubitemid 32758759)
16. Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, Ren CL, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics 2007;119:e531-e537. (Pubitemid 46407523)
17. Sanders DB, Li Z, Rock MJ, Brody AS, Farrell PM. The sensitivity of lung disease surrogates in detecting chest CT abnormalities in children with cystic fibrosis. Pediatr Pulmonol 2012;47:567-573.
18. Sanders DB, Li Z, Brody AS, Farrell PM. Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis. Am J Respir Crit Care Med 2011;184:816-821.
19. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145:32-38. (Pubitemid 38962449)
20. de Jong PA, Lindblad A, Rubin L, Hop WC, de Jongste JC, Brink M, Tiddens HA. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax 2006;61:80-85. (Pubitemid 43106983)
21. de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R, Paré PD, Tiddens HA. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23:93-97. (Pubitemid 38088503)
22. Terheggen-Lagro SW, Arets HG, van der Laag J, van der Ent CK. Radiological and functional changes over 3 years in young children with cystic fibrosis. Eur Respir J 2007;30:279-285. (Pubitemid 47194180)
23. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrell PM. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-287. (Pubitemid 32938876)
24. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Rock MJ, Splaingard ML. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 2003;168:1100-1108. (Pubitemid 37338940)
25. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003;36:230-240. (Pubitemid 37055971)
26. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns WT, Splaingard M, Mischler EH; Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med 1997;337:963-969. (Pubitemid 27425952)
27. Koscik RL, Farrell PM, Kosorok MR, Zaremba KM, Laxova A, Lai HC, Douglas JA, Rock MJ, Splaingard ML. Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics 2004;113:1549-1558. (Pubitemid 38697958)
28. Shoff SM, Ahn HY, Davis L, Lai H; Wisconsin CF Neonatal Screening Group. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis. Pediatrics 2006;117:391-400. (Pubitemid 46071601)
29. Tluczek A, Becker T, Laxova A, Grieve A, Racine Gilles CN, Rock MJ, Gershan WM, Green CG, Farrell PM. Relationships among healthrelated quality of life, pulmonary health, and newborn screening for cystic fibrosis. Chest 2011;140:170-177.
30. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr 2005;147 (3 Suppl):S11-S14. (Pubitemid 41400252)
31. Dankert-Roelse JE, Mérelle ME. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr 2005;147(3 Suppl):S15-S20. (Pubitemid 41400253)
32. Farrell PM; Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Improving the health of patients with cystic fibrosis through newborn screening. Adv Pediatr 2000;47:79-115.
33. Farrell P, Li Z, Sanders D, Lai H, Laxova A, Rock M, Levy H, Collins J, Férec C. Determinants of lung disease progression in children with CF [abstract]. J Cyst Fibros 2012;11(1 Suppl):S6.
34. Sanders DB, Li Z, Laxova A, Rock MJ, Farrell PM. Determinants of lung disease in children with CF [abstract]. Am J Respir Crit Care Med 2013;187:A1175.
35. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G, Laessig RH, Splaingard ML; Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves longterm growth. Pediatrics 2001;107:1-13. (Pubitemid 32055408)
36. Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A, Rock MJ, Splaingard M. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 1998;26:81-88. (Pubitemid 28381468)
37. Koscik RE, Kosorok MR, Farrell PM, Collins J, Peters ME, Laxova A, Green CG, Zeng L, Rusakow LS, Hardie RC, et al. Wisconsin cystic fibrosis chest radiograph scoring system: validation and standardization for application to longitudinal studies. Pediatr Pulmonol 2000;29:457-467. (Pubitemid 30346473)
38. Brasfield D, Hicks G, Soong S, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics 1979;63:24-29. (Pubitemid 9111195)
39. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001;57:120-125. (Pubitemid 32200145)
40. Lai HJ, Shoff SM, Farrell PM; Wisconsin Cystic Fibrosis Neonatal Screening Group. Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis. Pediatrics 2009;123:714-722.
41. Balfour-Lynn IM. Newborn screening for cystic fibrosis: evidence for benefit. Arch Dis Child 2008;93:7-10.
42. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, Collins J, Rock MJ, Splaingard ML. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-588. (Pubitemid 40171240)
43. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
44. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
45. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams- Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al.; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
46. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
47. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928.
48. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al.; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303:1707-1715.
49. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365: 1663-1672.
50. Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012;47:125-134.
51. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al.; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847-856.
52. Lai HC, Kosorok MR, Laxova A, Makholm LM, Farrell PM. Delayed diagnosis of US females with cystic fibrosis. Am J Epidemiol 2002; 156:165-173. (Pubitemid 34755955)
53. Viviani L, Bossi A, Assael BM; Italian Registry for Cystic Fibrosis Collaborative Group. Absence of a gender gap in survival: an analysis of the Italian registry for cystic fibrosis in the paediatric age. J Cyst Fibros 2011;10:313-317.
54. Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol 2002;156:397-401. (Pubitemid 34976977)
55. Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? Chest 2005;128:2824-2834. (Pubitemid 41507646)
56. Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012;129:e348-e355.
57. Farrell PM, Collins J, Broderick LS, Rock MJ, Li Z, Kosorok MR, Laxova A, Gershan WM, Brody AS. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology 2009;252:534-543.
58. Robinson TE, Leung AN, Chen X, Moss RB, Emond MJ. Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. Pediatr Pulmonol 2009;44:1107-1117.
59. Davis SD, Fordham LA, Brody AS, Noah TL, Retsch-Bogart GZ, Qaqish BF, Yankaskas BC, Johnson RC, Leigh MW. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007;175: 943-950. (Pubitemid 46684705)
60. Mott LS, Park J, Murray CP, Gangell CL, de Klerk NH, Robinson PJ, Robertson CF, Ranganathan SC, Sly PD, Stick SM; AREST CF (Australian Respiratory Early Surveillance Team for Cystic Fibrosis). Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012;67:509-516.
61. Augarten A, Paret G, Avneri I, Akons H, Aviram M, Bentur L, Blau H, Efrati O, Szeinberg A, Barak A, et al. Systemic inflammatory mediators and cystic fibrosis genotype. Clin Exp Med 2004;4:99-102. (Pubitemid 39506601)
62. Lai HC, Kosorok MR, Laxova A, Davis LA, FitzSimmon SC, Farrell PM. Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening. Pediatrics 2000;105:53-61. (Pubitemid 30035718)
63. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H; Clinical Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008;108:832-839. (Pubitemid 351602057)
64. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178:814-821.
65. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891-895.
66. Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Rosenfeld M, et al.; Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study Investigators. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013;68:643-651.
67. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005;147(3 Suppl):S30-S36. (Pubitemid 41400256)
68. Farrell PM, Mischler EH, Engle MJ, Brown DJ, Lau SM. Fatty acid abnormalities in cystic fibrosis. Pediatr Res 1985;19:104-109. (Pubitemid 15187486)
69. Sanders DB, Farrell PM. Transformative mutation specific pharmacotherapy for cystic fibrosis. BMJ 2012;344:e79.
70. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011;10:258-264.